60% equity transfer of Mike Pharmaceuticals in India Currently both parties are in the process of compliance

June 22 23:00:53, 2018

The reporter learned from Xiamen Maike Pharmaceutical Co., Ltd. on the 29th that the acquisition of 60% equity of Xiamen Maike Pharmaceutical Group by Matrix of India was finally settled. The two parties are currently handling the relevant compliance procedures, and the joint venture formed by both parties will be officially listed on December 27.
It is understood that Matrix is ​​a well-known pharmaceutical company in India that is proficient in the development and production of effective active ingredients (API) and is the third largest pharmaceutical company in India. Its products are sold in more than 70 countries and regions. This year, Matrix has undergone a massive expansion. In September alone, it announced three mergers and acquisitions. In addition to the acquisition of a 60% equity interest in Xiamen Meike Pharmaceutical Group, the company also said that it has acquired the Explora Laboratories in Switzerland and has entered into two joint ventures with Aspen Pharmaceuticals in South Africa.
Mike Pharmaceutical Group is a privately-owned pharmaceutical industry group in China. It was established in 1997. Currently, the company has 7 holding companies in China. The main medical products include various pharmaceutical intermediates, APIs and finished drugs, and Xiamen Mike Pharmaceutical Co., Ltd. The company is a national designated producer of anti-HIV drugs. At present, the anti-HIV medicines of Mike Pharmaceutical have been sold to countries such as Brazil, South Africa and India. In July this year, they also signed a long-term cooperation agreement on anti-AIDS drugs with the US Clinton Foundation. Mike Pharmaceuticals provides anti-AI treatment drugs to Clinton Foundation's supplier partners and over 40 member countries at very competitive prices, helping the Clinton Foundation and its partners to further reduce the prices of HIV/AIDS first-line and second-line drugs .